WO2000046344A3 - Non-stochastic generation of genetic vaccines and enzymes - Google Patents

Non-stochastic generation of genetic vaccines and enzymes Download PDF

Info

Publication number
WO2000046344A3
WO2000046344A3 PCT/US2000/003086 US0003086W WO0046344A3 WO 2000046344 A3 WO2000046344 A3 WO 2000046344A3 US 0003086 W US0003086 W US 0003086W WO 0046344 A3 WO0046344 A3 WO 0046344A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
enzymes
genetic vaccines
stochastic
provides methods
Prior art date
Application number
PCT/US2000/003086
Other languages
French (fr)
Other versions
WO2000046344A2 (en
Inventor
Jay M Short
Original Assignee
Diversa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diversa Corp filed Critical Diversa Corp
Priority to IL138206A priority Critical patent/IL138206A/en
Priority to JP2000597406A priority patent/JP2003524392A/en
Priority to CA002325351A priority patent/CA2325351C/en
Priority to MXPA00009723A priority patent/MXPA00009723A/en
Priority to EP00913378A priority patent/EP1073710A4/en
Priority to AU34839/00A priority patent/AU3483900A/en
Publication of WO2000046344A2 publication Critical patent/WO2000046344A2/en
Publication of WO2000046344A3 publication Critical patent/WO2000046344A3/en
Priority to US10/151,469 priority patent/US20030219752A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/11—Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
    • C12Y301/11002—Exodeoxyribonuclease III (3.1.11.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by use of non-stochastic methods of directed evolution (DirectEvolutionTM). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation MutagenesisTM) and non-stochastic polynucleotide reassembly (GeneReassemblyTM). Through use of the claimed methods, genetic vaccines, enzymes, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. This invention provides methods of obtaining novel enzymes that have optimized physical and/or biological properties. Furthermore, this invention provides methods of obtaining a variety of novel biologically active molecules, in the fields of antibiotics, pharmacotherapeutics, and transgenic traits.
PCT/US2000/003086 1995-12-07 2000-02-04 Non-stochastic generation of genetic vaccines and enzymes WO2000046344A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IL138206A IL138206A (en) 1999-02-04 2000-02-04 Methods for non-stochastic generation of progeny polypeptides and hybrid polynucleotides
JP2000597406A JP2003524392A (en) 1999-02-04 2000-02-04 Non-stochastic generation of genetic vaccines and enzymes
CA002325351A CA2325351C (en) 1999-02-04 2000-02-04 Non-stochastic generation of genetic vaccines and enzymes
MXPA00009723A MXPA00009723A (en) 1999-02-04 2000-02-04 Non-stochastic generation of genetic vaccines and enzymes.
EP00913378A EP1073710A4 (en) 1999-02-04 2000-02-04 Non-stochastic generation of genetic vaccines and enzymes
AU34839/00A AU3483900A (en) 1999-02-04 2000-02-04 Non-stochastic generation of genetic vaccines and enzymes
US10/151,469 US20030219752A1 (en) 1995-12-07 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/246,178 US6171820B1 (en) 1995-12-07 1999-02-04 Saturation mutagenesis in directed evolution
US09/246,178 1999-02-04
US09/267,118 1999-03-09
US09/267,860 1999-03-26
US09/332,835 1999-06-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1997/012239 Continuation-In-Part WO1998001581A1 (en) 1996-07-09 1997-07-09 Method of dna shuffling with polynucleotides produced by blockingor interrupting a synthesis or amplification process
US10/151,469 Continuation-In-Part US20030219752A1 (en) 1995-12-07 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Publications (2)

Publication Number Publication Date
WO2000046344A2 WO2000046344A2 (en) 2000-08-10
WO2000046344A3 true WO2000046344A3 (en) 2000-12-28

Family

ID=22929614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003086 WO2000046344A2 (en) 1995-12-07 2000-02-04 Non-stochastic generation of genetic vaccines and enzymes

Country Status (5)

Country Link
US (1) US6171820B1 (en)
JP (2) JP2003524392A (en)
AU (1) AU3483900A (en)
CA (1) CA2325351C (en)
WO (1) WO2000046344A2 (en)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6165793A (en) * 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6740506B2 (en) * 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6764835B2 (en) * 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20070009930A1 (en) * 1996-12-18 2007-01-11 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
KR100570935B1 (en) 1997-01-17 2006-04-13 맥시겐, 인크. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) * 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6159688A (en) 1997-03-18 2000-12-12 Novo Nordisk A/S Methods of producing polynucleotide variants
WO1999021977A1 (en) * 1997-10-24 1999-05-06 Life Technologies, Inc. Recombinational cloning using nucleic acids having recombination sites
KR20010032861A (en) 1997-12-08 2001-04-25 캘리포니아 인스티튜트 오브 테크놀로지 Method for creating polynucleotide and polypeptide sequences
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
WO1999057128A1 (en) 1998-05-01 1999-11-11 Maxygen, Inc. Optimization of pest resistance genes using dna shuffling
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US6951719B1 (en) * 1999-08-11 2005-10-04 Proteus S.A. Process for obtaining recombined nucleotide sequences in vitro, libraries of sequences and sequences thus obtained
US20030104417A1 (en) * 1998-08-12 2003-06-05 Proteus S.A. Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides
US6991922B2 (en) * 1998-08-12 2006-01-31 Proteus S.A. Process for in vitro creation of recombinant polynucleotide sequences by oriented ligation
US20030092023A1 (en) * 1998-08-12 2003-05-15 Daniel Dupret Method of shuffling polynucleotides using templates
US20040005673A1 (en) * 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
DE60042730D1 (en) * 1999-01-05 2009-09-24 Univ Boston IMPROVED CLONING PROCESS
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
EP1151409A1 (en) * 1999-01-18 2001-11-07 Maxygen, Inc. Methods of populating data stuctures for use in evolutionary simulations
US20070065838A1 (en) * 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
JP3399518B2 (en) * 1999-03-03 2003-04-21 インターナショナル・ビジネス・マシーンズ・コーポレーション Semiconductor structure and method of manufacturing the same
EP1165775A2 (en) 1999-03-05 2002-01-02 Maxygen, Inc. Recombination of insertion modified nucleic acids
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
SG121902A1 (en) * 2000-01-11 2006-05-26 Maxygen Inc Integrated systems for diversity generation and screening
AU2001241939A1 (en) * 2000-02-28 2001-09-12 Maxygen, Inc. Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
AU2001287273A1 (en) * 2000-03-24 2001-10-08 Maxygen, Inc. Methods for modulating cellular and organismal phenotypes
US6479262B1 (en) 2000-05-16 2002-11-12 Hercules, Incorporated Solid phase enzymatic assembly of polynucleotides
WO2002000897A2 (en) * 2000-06-23 2002-01-03 Maxygen, Inc. Novel chimeric promoters
AU2001272978A1 (en) * 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
WO2002004629A2 (en) * 2000-07-07 2002-01-17 Maxygen, Inc. Molecular breeding of transposable elements
US6858422B2 (en) * 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
US7435562B2 (en) * 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US7198924B2 (en) * 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO2002016583A2 (en) * 2000-08-24 2002-02-28 Maxygen, Inc. Constructs and their use in metabolic pathway engineering
JP2002083691A (en) * 2000-09-06 2002-03-22 Sharp Corp Active matrix driven organic led display unit and its manufacturing method
AU2004260931B9 (en) 2003-04-29 2012-01-19 E.I. Du Pont De Nemours And Company Novel glyphosate-N-acetyltransferase (GAT) genes
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
CA2436214C (en) * 2001-02-02 2012-12-04 Large Scale Biology Corporation A method of increasing complementarity in a heteroduplex polynucleotide
US20030036854A1 (en) * 2001-02-06 2003-02-20 The Penn State Research Foundation Apparatus and method for designing proteins and protein libraries
EP1277835A1 (en) * 2001-07-19 2003-01-22 Libragen Methods of creating genetic diversity
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
ES2538342T3 (en) 2001-10-10 2015-06-19 Ratiopharm Gmbh Remodeling and glycoconjugation of follicle stimulating hormone (FSH)
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
EP2305311A3 (en) 2001-10-10 2011-07-20 BioGeneriX AG Glycoconjugation of peptides
AU2002364518A1 (en) * 2001-12-03 2003-06-17 Diversa Corporation Chromosomal saturation mutagenesis
TWI262083B (en) * 2001-12-28 2006-09-21 Syngenta Participations Ag Microbially-expressed thermotolerant phytase for animal feed
US20040009498A1 (en) * 2002-01-14 2004-01-15 Diversa Corporation Chimeric antigen binding molecules and methods for making and using them
AU2002306484A1 (en) 2002-02-13 2003-09-04 Dow Global Technologies Inc. Over-expression of extremozyme genes in pseudomonads and closely related bacteria
JP2006502695A (en) * 2002-02-15 2006-01-26 ダイヴァーサ コーポレイション Chimeric cannula protein, nucleic acid encoding the same, method for producing the same and method for using the same
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20030166010A1 (en) * 2002-02-25 2003-09-04 Affholter Joseph A. Custom ligand design for biomolecular filtration and purification for bioseperation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003075129A2 (en) 2002-03-01 2003-09-12 Maxygen, Inc. Methods, systems, and software for identifying functional bio-molecules
US20030199068A1 (en) * 2002-03-05 2003-10-23 Bott Richard R. High throughput mutagenesis screening method
US20030171543A1 (en) * 2002-03-05 2003-09-11 Bott Richard R. High throughput mutagenesis screening method
EP1488335A4 (en) 2002-03-09 2006-11-15 Maxygen Inc Optimization of crossover points for directed evolution
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
CN102174546A (en) 2002-04-19 2011-09-07 维莱尼姆公司 Phospholipases, nucleic acids encoding them and methods for making and using them
JP4372679B2 (en) * 2002-05-17 2009-11-25 アリゲーター・バイオサイエンス・アーベー In vitro molecular evolution of protein function
AU2003253992A1 (en) * 2002-07-18 2004-02-09 Robert P. Bennett Viral vectors containing recombination sites
EP1546349A1 (en) * 2002-08-02 2005-06-29 Aromagen Corporation Methods for making (-) -menthol and oxygenated menthane compounds
BR0313281A (en) 2002-08-06 2007-07-24 Verdia Inc ap1 amine oxidase variants
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
DK2853593T3 (en) 2003-03-07 2018-01-08 Dsm Ip Assets Bv Hydrolases, nucleic acids encoding them, and processes for their preparation and use
US20050095615A1 (en) * 2003-06-26 2005-05-05 Welch Peter J. Methods and compositions for detecting promoter activity and expressing fusion proteins
CA2546698A1 (en) * 2003-11-20 2005-06-02 Agency For Science, Technology And Research Method
JP2007512838A (en) * 2003-12-01 2007-05-24 インヴィトロジェン コーポレーション Nucleic acid molecules containing recombination sites and methods of use thereof
US7204950B2 (en) * 2003-12-19 2007-04-17 Pepsico, Inc. Dispensing package
WO2005082077A2 (en) 2004-02-25 2005-09-09 Pioneer Hi-Bred International, Inc. Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof
US7183089B2 (en) 2004-05-21 2007-02-27 The Regents Of The University Of California Method for enhancing production of isoprenoid compounds
AR049214A1 (en) 2004-06-09 2006-07-05 Pioneer Hi Bred Int PEPTIDES OF TRANSIT TO PLASTIDES
CA2583735A1 (en) 2004-10-27 2006-10-19 The Scripps Research Institute Orthogonal translation components for the in vivo incorporation of unnatural amino acids
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2006053131A1 (en) * 2004-11-11 2006-05-18 Modular Genetics, Inc. Ladder assembly and system for generating diversity
CA2614769A1 (en) 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
CA2611859C (en) 2005-03-15 2015-03-31 Verenium Corporation Cellulases, nucleic acids encoding them and methods for making and using them
US20070184472A1 (en) * 2005-06-08 2007-08-09 Toagosei Co., Ltd Method of purifying environmental dna and method of efficiently screening for protein-encoding gene from environmental dna
PL2314623T3 (en) 2005-06-21 2012-11-30 Xoma Us Llc IL-1beta binding antibodies and fragments thereof
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
US20090324574A1 (en) 2006-02-02 2009-12-31 Verenium Corporation Esterases and Related Nucleic Acids and Methods
MY160772A (en) 2006-02-10 2017-03-15 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
PL1989302T3 (en) 2006-02-14 2019-03-29 Bp Corp North America Inc Xylanases, nucleic acids encoding them and methods for making and using them
EP3153580A3 (en) 2006-03-07 2017-04-19 BASF Enzymes LLC Aldolases, nucleic acids encoding them and methods for making and using them
EP2112227B1 (en) 2006-03-07 2013-05-15 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
EP2522678A1 (en) 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
WO2007146975A2 (en) * 2006-06-13 2007-12-21 Athenix Corporation Methods for generating genetic diversity by permutational mutagenesis
AU2007356171B8 (en) 2006-08-04 2014-01-16 Bp Corporation North America Inc. Glucanases, nucleic acids encoding them, and methods for making and using them
CN101558154B (en) 2006-09-21 2016-02-24 帝斯曼知识产权资产管理有限公司 Phospholipid hydrolase, encode their nucleic acid and methods for making and using same thereof
MX2009003032A (en) 2006-09-21 2009-11-18 Verenium Corp Phytases, nucleic acids encoding them and methods for making and using them.
WO2008079466A1 (en) 2006-12-20 2008-07-03 Mmr Information Systems, Inc. Antibodies and methods for making and using them
PL2479267T3 (en) 2006-12-21 2017-06-30 Basf Enzymes Llc Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them
BRPI0807132A2 (en) 2007-01-30 2018-12-04 Syngenta Participations Ag enzymes for the treatment of lignocellulosics, nucleic acids encoding them, and methods and use thereof
HRP20181319T4 (en) 2007-03-30 2024-02-16 The Research Foundation Of The State University Of New York Attenuated viruses useful for vaccines
NZ582876A (en) 2007-07-31 2012-07-27 Bp Corp North America Inc Tailored multi-site combinatorial assembly of polynucleotides
NZ601191A (en) 2007-10-03 2014-01-31 Verenium Corp Xylanases, nucleic acids encoding them and methods for making and using them
CA2704271C (en) 2007-12-03 2016-07-19 Syngenta Participations Ag Engineering enzymatically susceptible phytases
EP2242843B1 (en) * 2007-12-31 2015-05-27 XOMA Technology Ltd. Methods and materials for targeted mutagenesis
US8541220B2 (en) 2008-01-03 2013-09-24 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
EP2865750A3 (en) 2008-01-03 2015-08-05 BASF Enzymes LLC Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
WO2009095796A2 (en) * 2008-01-28 2009-08-06 The University Of British Columbia Tapasin augmentation for enhanced immune response
CN102046656A (en) 2008-03-28 2011-05-04 航道生物技术有限责任公司 Neutralizing molecules to viral antigens
CN102112624A (en) * 2008-05-30 2011-06-29 麻省理工学院 Compositions and methods for spatial separation and screening of cells
US20090312196A1 (en) * 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US8383346B2 (en) * 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
PE20110942A1 (en) * 2008-12-02 2011-12-30 Consejo Nac Invest Cient Tec MODIFIED PROTOZOO THAT EXPRESSES MULTIPLE VARIABLE SURFACE PROTEINS (VSP), UNDERSTANDING IMMUNOGENIC COMPOSITION AND PROCEDURES
EP2430042A1 (en) 2009-05-12 2012-03-21 Council of Scientific & Industrial Research Lipa and its variant useful for biofuel production
JP2012527247A (en) 2009-05-21 2012-11-08 ヴェレニウム コーポレイション Phytase, nucleic acid encoding phytase and method for producing and using the same
KR101823872B1 (en) 2009-07-17 2018-01-31 바이오아트라, 엘엘씨 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
UA109884C2 (en) 2009-10-16 2015-10-26 A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
UA111708C2 (en) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. METHOD OF OIL REFINING
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
WO2012009026A2 (en) 2010-07-16 2012-01-19 Bioatla Llc Novel methods of protein evolution
WO2012021797A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Methods and compositions for targeting sequences of interest to the chloroplast
CA2811787A1 (en) 2010-10-06 2012-04-19 Bp Corporation North America Inc. Variant cbh i polypeptides
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
US20140182011A1 (en) 2011-11-03 2014-06-26 The University Of Hong Kong Methods Using Acyl-Coenzyme A-Binding Proteins to Enchance Drought Tolerance in Genetically Modified Plants
CN104540939A (en) 2012-03-16 2015-04-22 Bp北美公司 Polypeptides having endoglucanase activity
WO2013166113A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
MX2019001355A (en) 2012-05-10 2023-01-17 Bioatla Llc Multi-specific monoclonal antibodies.
ES2693461T3 (en) 2012-08-16 2018-12-11 Bangladesh Jute Research Institute Enzymes that degrade cellulose and / or hemicelluloses of Macrophomina phaseolina and uses thereof
IN2015DN02049A (en) 2012-08-16 2015-08-14 Bangladesh Jute Res Inst
US10253325B2 (en) 2012-12-19 2019-04-09 Boston Medical Center Corporation Methods for elevating fat/oil content in plants
US9684771B2 (en) 2013-01-31 2017-06-20 Codexis, Inc. Methods, systems, and software for identifying bio-molecules using models of multiplicative form
GB201308828D0 (en) 2013-03-12 2013-07-03 Verenium Corp Phytase
EP2970935A1 (en) 2013-03-14 2016-01-20 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
GB201308843D0 (en) 2013-03-14 2013-07-03 Verenium Corp Phytase formulation
CA2905595A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
US10093909B2 (en) 2013-07-25 2018-10-09 Basf Enzymes Llc Phytase
EP3447493B1 (en) 2014-01-07 2020-05-13 Bioatla, LLC Proteins targeting orthologs
EP3359669B1 (en) 2015-10-06 2020-05-13 Pierce Biotechnology, Inc. Devices and methods for producing proteins
AU2016343738B2 (en) 2015-10-30 2021-05-13 Beth Israel Deaconess Medical Center, Inc. Methods for determination of bioactivity, quantity, removal, or inactivation of cereal amylase trypsin inhibitors in cereals, flours, plants, and complex foods
KR20190129032A (en) 2016-12-28 2019-11-19 인벡스, 인크. Influenza vaccine
MX2020004318A (en) 2017-10-25 2020-08-13 Basf Se Beta-amylase enzymes.
CN111492063A (en) * 2017-12-20 2020-08-04 巴斯夫欧洲公司 Gene Site Saturation Mutagenesis (GSSM) method
CN112368375A (en) 2018-04-26 2021-02-12 巴斯夫欧洲公司 Lipase enzyme
EP3788145A1 (en) 2018-05-03 2021-03-10 Basf Se Amylase enzymes
WO2019229101A1 (en) 2018-05-29 2019-12-05 Basf Se Amylase enzymes
CN112996915A (en) 2018-09-07 2021-06-18 巴斯夫植物科学有限公司 Improved methods for producing high levels of PUFAs in plants
WO2020049155A1 (en) 2018-09-07 2020-03-12 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
US20210317467A1 (en) 2018-09-07 2021-10-14 Basf Plant Science Copmany Gmbh Improved method for the production of high levels of pufa in plants
EP3938504A1 (en) 2019-03-11 2022-01-19 Basf Se Amylases and methods for making and using them
US20220220463A1 (en) 2019-04-23 2022-07-14 Basf Se Beta-amylase variants
BR112022011895A2 (en) 2019-12-20 2022-09-06 Basf Se DECREASE IN TERPENE TOXIDITY AND INCREASED POTENTIAL PRODUCTION IN MICROORGANISMS
US20230235310A1 (en) 2020-06-04 2023-07-27 Isobionics B.V. Synthetic santalene synthases
EP4015626A1 (en) 2020-12-18 2022-06-22 Isobionics B.V. Enzymes and methods for fermentative production of monoterpene esters
CN117795087A (en) 2021-08-02 2024-03-29 巴斯夫欧洲公司 Novel production of aromatic compounds with violet subunit ethane synthase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959312A (en) * 1985-05-31 1990-09-25 The University Of Tennessee Research Corporation Full spectrum mutagenesis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
EP0672145B1 (en) 1992-11-24 2003-04-23 G.D. Searle & Co. Interleukin-3 (il-3) multiple mutation polypeptides
BR9407767A (en) * 1993-10-08 1997-03-18 Novo Nordisk As Enzyme & -amylase variant use the same DNA vector expression construct the recombinant cell processes to produce a hybrid & -amylase hybrid and to prepare a variant of a detergent & -amylase additive and detergent compositions
US6187579B1 (en) 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5389537A (en) 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity
JPH10504718A (en) 1994-08-18 1998-05-12 サイトゲン コーポレーション Peptide libraries as syngene sources
AU3719395A (en) 1994-09-21 1996-04-09 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US5885577A (en) 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
ES2236634T3 (en) 1997-04-07 2005-07-16 Genentech, Inc. ANTI-VEGF ANTIBODIES.
PT975771E (en) 1997-04-18 2007-10-01 Biogen Idec Inc Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
AU7171098A (en) 1997-05-01 1998-11-24 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
AU1526099A (en) * 1997-11-17 1999-06-07 Novo Nordisk Biotech, Inc. Polypeptides having 5-aminolevulinic acid synthase activity and nucleic acids encoding same
KR100556071B1 (en) * 1997-12-16 2006-03-10 노보자임스 에이/에스 Polypeptides having signal peptide activity and nucleic acids encoding same
EP1045915A2 (en) 1998-01-15 2000-10-25 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959312A (en) * 1985-05-31 1990-09-25 The University Of Tennessee Research Corporation Full spectrum mutagenesis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CWIRLA ET AL.: "Peptides on phage: A vast library of peptides for identifying ligands", PROC. NATL. ACAD. SCI. USA,, vol. 87, August 1990 (1990-08-01), pages 6378 - 6382, XP000141872 *
HILL ET AL.: "Mutagenesis with degenerate oligonucleotides: An efficient method for saturating a defined DNA region with base pair substitutions", METHODS IN ENZYMOLOGY,, vol. 155, 1987, pages 558 - 569, XP002929872 *
MURRAY ET AL.: "Saturation mutagenesis of a major histocompatibility complex protein domain: Identification of a single conserved amino acid important for allorecognition", PROC. NATL. ACAD. SCI. USA,, vol. 85, May 1988 (1988-05-01), pages 3535 - 3539, XP002929873 *

Also Published As

Publication number Publication date
AU3483900A (en) 2000-08-25
CA2325351C (en) 2005-02-01
WO2000046344A2 (en) 2000-08-10
US6171820B1 (en) 2001-01-09
JP2003524392A (en) 2003-08-19
JP2005245453A (en) 2005-09-15
CA2325351A1 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
WO2000046344A3 (en) Non-stochastic generation of genetic vaccines and enzymes
EP2397549A3 (en) Non-stochastic generation of genetic vaccines and enzymes
WO2000053744A3 (en) End selection in directed evolution
WO1999041369A3 (en) Genetic vaccine vector engineering
WO2003101375A3 (en) Immunostimulatory oligonucleotides and uses thereof
AU2001254624A1 (en) Human coagulation factor vii variants
MXPA02006888A (en) Recombinant flaviviruses and methods of use thereof.
IL193087A0 (en) Dan from a reconbinant poxvirus expressing homologous genes inserted into the poxviral genome
WO2001019859A3 (en) LEPIDOPTERAN-ACTIVE BACILLUS THURINGIENSIS δ-ENDOTOXIN COMPOSITIONS AND METHODS OF USE
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
ATE338110T1 (en) IMPROVED PHYTASES
WO2004037977A3 (en) Use of chimeric nucleases to stimulate gene targeting
EP1085089A3 (en) Human cyclic nucleotide phosphodiesterase
MXPA02012937A (en) Combinations of active ingredients, which exhibit insecticidal and acaricidal properties.
WO1999057282A3 (en) Pesticidal toxins and nucleotide sequences which encode these toxins
WO2003048205A3 (en) Novel proteins with il-6 inhibiting activity
WO2000053776A3 (en) Human kallikrein-like genes
WO2002016549A3 (en) METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
EP1613345A4 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
AP1502A (en) Genes and proteins, and their uses.
CN106119145A (en) A kind of Corynebacterium glutamicum mutant and application
WO2004072225A3 (en) Transgenic fungi expressing bcl-2 and methods of using bcl-2 or portions thereof for improving biomass production, survival, longevity, stress resistance and pathogenicity of fungi
WO2002012468A3 (en) 2,5-dkg permeases
WO2006029343A3 (en) Peptides that selectively home to heart vasculature and related conjugates and methods
TW200509964A (en) VP1 of foot-and-mouth disease virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 138206

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2325351

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009723

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000913378

Country of ref document: EP

Ref document number: 34839/00

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000913378

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)